How does Zinbryta work?
Medically reviewed by Judith Stewart, BPharm. Last updated on March 11, 2021.
Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody for the treatment of adults with relapsing forms of multiple sclerosis (MS). It is thought to work by decreasing T-cells and pro-inflammatory lymphoid tissue inducer cells, and increasing CD56bright natural killer (NK) cells, important cells that help regulate the immune system.
Zinbryta should only be used in patients who have had an inadequate response to two or more multiple sclerosis drugs.
The Zinbryta product label carries a boxed warning advising the serious safety risks, including liver injury and immune disorders.
Zinbryta is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy.
Related Medical Questions
- What are the new drugs used for multiple sclerosis (MS)?
- Prednisone vs Prednisolone - What's the difference?
- How much does an Ocrevus infusion cost?
- Is Tecfidera an immunosuppressant?
- Is Ocrevus a form of chemotherapy?
- How long does it take Ocrevus to work?
- How do Vumerity and Tecfidera compare for multiple sclerosis (MS)?
- How does Ocrevus work for MS?
- Can I stop taking Tecfidera? What happens if I do?
- How long does an Ocrevus infusion take?
- Can you drink alcohol while taking Tecfidera?
- What are the side effects of marijuana?
- How long can you take Tecfidera?
- What causes flushing with Tecfidera?
- Gilenya vs Tecfidera. How do they compare?
- Zinbryta Information for Consumers
- Zinbryta Information for Healthcare Professionals (includes dosage details)
- Side Effects of Zinbryta (detailed)